A recommendation regarding the use of pembrolizumab in treatment-naïve, advanced RET-rearranged lung cancers with high PD-L1 expression cannot be made on the basis of our findings, although its use should be approached with caution. The gene discussed is CD274; the disease is lung carcinoma.